Human STEAP3 Full Length Protein (VLP)

Application

1. Immunization
2. FACS
3. Elisa

Synonym

STEAP3

Source

Human STEAP3 Full Length Protein (VLP) (ST3-H52P3) is expressed from human 293 cells (HEK293). It contains AA Pro 2 - Val 488 (Accession # Q658P3-1).

Predicted N-terminus: Met

Molecular Characterization

1. Structure

   

   Virus-like particles (VLPs) are protein particles that mimic the shape of viruses but lack a viral genome, and incorporating transmembrane proteins on the external surface.

2. Synthesis Process

   

   Virus-like particles (VLPs) are non-infectious structures that mimic the shape of viruses but lack a viral genome. During VLP production in cells systems, VLPs self-assemble into 100-200 nm protein particles, and incorporate transmembrane proteins into a VLP-MP complex, resulting in presentation of the protein on the external surface of the VLP. Their repetitive, multivalent surface display and strong immunogenicity, making them an excellent candidate for immunization.

Endotoxin

Less than 1.0 EU per μg by the LAL method / rFC method.

Formulation

The VLPs are highly immunogenic, so the immunization strategy should be optimized (antigen dose, regimen and adjuvant).

Supplied as 0.2 μm filtered solution in PBS, Arginine, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

Shipping

This product is supplied and shipped with dry ice, please inquire the shipping cost.

Storage

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

1. The product MUST be stored at -70°C or lower upon receipt;
2. -70°C for 12 months under sterile conditions.

ACRO Quality Management System

1. QMS(ISO, GMP)
2. Quality Advantages
3. Quality Control Process